MYD88 L265P

CI-VAR-00002325Explore in graph →NP_002459.2:p.L265PNM_002468.4:c.794T>CClinVar 37055 CIViC 424 rs387907272

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Lymphocytic Leukemia1
MYD88 L265P	(prognostic)	Prognostic	B	Supports Better Outcome	2	accepted	EID1489 MYD88 mutations were identified in 24 of 1080 screened CLLs. They were exclusively seen in instances of mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for better out… (full text at CIViC) PMID 24943832 · Baliakas et al., 2015 · Open in CIViC	civic
Diffuse Large B-Cell Lymphoma1
MYD88 L265P	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID9376 A meta-analysis of 40 published studies on 2736 DLBCL patients. The MYD88 L265P mutation was significantly associated with old age and poor overall survival, but not with sex and clinical stage. This … (full text at CIViC) PMID 28496180 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
37055	Uncertain significance	criteria provided, multiple submitters, no conflicts	2	Macroglobulinemia, Waldenstrom, somatic; Pyogenic bacterial infections due to MyD88 deficiency; Malignant lymphoma, large B-cell, diffuse; Neoplasm	germline/somatic	5	Jun 03, 2023	clinvar

Lymphoplasmacytic Lymphoma2
MYD88 L265P	Ibrutinib	Predictive	B	Supports Sensitivity Response	4	accepted	EID986 A prospective study of ibrutinib in 63 symptomatic patients with Waldenström's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with M… (full text at CIViC) PMID 25853747 · Treon et al., 2015 · Open in CIViC	civic
MYD88 L265P	IMG-2005-5 + IRAK-1/4 InhibitorSubstitutes	Predictive	D	Supports Sensitivity Response	1	accepted	EID1641 In a study of 30 patients with Waldenström’s macroglobulinemia, 87% had MYD88(L265P) mutations. Waldenstrom macroglobulinemia cells expressing MYD88(L265P) were treated with an MYD88 homodimerization… (full text at CIViC) PMID 22931316 · Treon et al., 2012 · Open in CIViC	civic